Navigation Links
Major Discovery Raises Prospect of Better Patient Care By Improving,Platelet Life Span

MELBOURNE, Australia, March 23, 2007 /PRNewswire/ -- Scientists at WEHI have made a discovery with potentially profound implications for the care of patients, especially those undergoing cancer chemotherapy.

The research team led by Drs Benjamin Kile and David Huang has discovered that platelet life span is controlled by two key molecules. The discovery raises the prospect of developing a new drug to prolong the life span of platelets stored in blood banks, effectively increasing the availability of this life-saving blood product.

An undesirable side effect of cancer chemotherapy is extensive bruising and potentially life-threatening bleeding. This is caused by the unintended depletion of platelets, tiny circulating blood cells that are essential for blood clotting and wound healing. Consequently, the well being of some patients depends upon platelet transfusions, particularly during the vulnerable periods that follow anti-cancer treatment. The significant demand for high quality platelets, coupled with their short shelf life of only five days, presents major logistical challenges in clinical practice.

The scientific team has found that two specialised molecules act in opposition to each other to control platelet life span by regulating the process known as "apoptosis." This term refers to the normal and healthy self destruction of old, damaged and surplus cells. One protein (known as Bcl-xL) acts to preserve the life of the platelet, while the other protein (Bak) prepares the cell to self-destruct after its usual life span within the body - - about a week.

WEHI's Dr David Huang said, "Apoptosis is an essential process, common in other cells, but the central role it plays in controlling the life span of the highly specialised platelet has not been previously appreciated. With this new knowledge, we are in a much stronger position to devise better therapies for the management of plate let-related diseases."

Dr Kile added, "For fifty years doctors have speculated about what controls platelet life span. We now know the identity of the precise molecular switch responsible. The team is now actively pursuing a drug development program aimed at manipulating this switch in order to prolong the life span of blood bank platelets, increasing their availability to patients receiving cancer treatment and others in danger of serious bleeding".

At the opposite end of the scale, shortening platelet life span may be useful in the treatment of other diseases. For instance, too many platelets can trigger dangerous blood clots leading to strokes or heart attacks. Reducing platelet life span may therefore prove valuable in the prevention and management of these life-threatening conditions.

Refer to the illustration which can be viewed at http://www.asianetnews.net

The scientific research was generously funded by the Australian National Health and Medical Research Council (NHMRC); the State Government of Victoria (DIIRD); the Australian Research Council (ARC); the Australian Cancer Research Foundation (ACRF); the Cancer Council of Victoria (CCV); the National Cancer Institute (US); the US-based Leukemia and Lymphoma Society (www.lls.org); and MuriGen Pty Ltd (www.murigen.com.au), a company based at the WEHI Biotechnology Centre in Bundoora, Victoria.

The scientific teams, headed by Dr Kile and Dr Huang and based at WEHI, include: Dr Kylie Mason, Dr Marina Carpinelli, Dr Jamie Fletcher, Dr Janelle Collinge, Ms Adrienne Hilton, Ms Sarah Ellis (Peter MacCallum Cancer Centre), Ms Priscilla Kelly, Dr Paul Ekert (Children's Cancer Centre, Royal Children's Hospital), Professor Donald Metcalf and Dr Andrew Roberts.

The findings of the scientific team are published in the 23 March 2007 issue of the prestigious international journal, Cell.

    Dr Benjamin Kile and Dr David Huang are available for interview.


    Contact:

    Mr Brad Allan,

    WEHI Communications Manager

    Telephone: +61 3 9345 2345; mobile 0403036116.

    Email 

allan@wehi.edu.au

Eliza Hall Institute Of Medical Research (WEHI)

CONTACT: Mr Brad Allan, WEHI Communications Manager, +61 3 9345 2345, ormobile, 0403036116, or allan@wehi.edu.au

Web site: http://www.asianetnews.net/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
2. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
3. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
4. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
5. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
6. Major Manufacturer of Unapproved and Adulterated Drugs
7. Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data
8. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
9. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
10. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
11. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):